International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn

Lani Lieberman1,2,3 | Enrico Lopriore4 | Jillian M. Baker5,6 | Rachel S. Bercovitz7 | Robert D. Christensen8,9 | Gemma Crichton10 | Meghan Delaney11,12 | Ruchika Goel13,14 | Jeanne E. Hendrickson15 | Amy Keir16,17 | Denise Landry18 | Ursula La Rocca19,20 | Brigitte Lemyre21 | Rolf F. Maier22 | Eduardo Muniz-Diaz23 | Susan Nahirniak24 | Helen V. New25,26 | Katerina Pavenski27 | Maria Cristina Pessoa dos Santos28 | Glenn Ramsey29 | Nadine Shehata30 | for the International Collaboration for Transfusion Medicine Guidelines (ICTMG)

1Department of Clinical Pathology, University Health Network, Toronto, Ontario, Canada
2Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada
3Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
4Division of Neonatology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
5Department of Pediatrics, Unity Health Toronto (St. Michael’s Hospital), Toronto, Ontario, Canada
6Division of Haematology-Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
7Division of Hematology, Oncology, and Stem Cell Transplant, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
8Divisions of Neonatology and Hematology/Oncology, University of Utah Health, Salt Lake City, UT, USA
9Divisions of Neonatology and Hematology/Oncology, University of Utah Health, Salt Lake City, UT, USA
10Department of Women and Newborn’s Research, Intermountain Healthcare, Salt Lake City, Utah, USA
11Department of Haematology, Royal Children’s Hospital, Melbourne, Australia
12Division of Pathology & Laboratory Medicine, Children’s National Hospital, Washington, District of Columbia, USA
13Division of Pathology & Pediatrics, The George Washington University Health Sciences, Washington, District of Columbia, USA
14Division of Transfusion Medicine, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
15Simmons Cancer Institute at SIU School of Medicine, Springfield, Illinois, USA
16Departments of Laboratory Medicine and Pediatrics, Yale University, New Haven, Connecticut, USA
17Adelaide Medical School and the Robinson Research Institute, the University of Adelaide, North Adelaide, South Australia, Australia
18SAHMRI Women and Kids, South Australian Health and Medical Institute, North Adelaide, South Australia, Australia
19Adelaide Medical School and the Robinson Research Institute, the University of Adelaide, North Adelaide, South Australia, Australia
20Canadian Blood Services, Ottawa, Ontario, Canada
21Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
22Italian National Blood Centre, National Institute of Health, Rome, Italy
23Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
24Children’s Hospital, University Hospital, Philippus University, Marburg, Germany
25Department of Immunohematology, Blood and Tissue Bank of Catalonia, Barcelona, Spain
26Alberta Precision Laboratories and Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
27Clinical Directorate, NHS Blood and Transplant, London, UK
28Centre for Haematology, Imperial College London, London, UK
29Department of Laboratory Medicine and Pathology, Unity Health Toronto (St. Michael’s Hospital), Toronto, Ontario, Canada
30IFF/Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil

Abbreviations: AAP, American Academy of Paediatrics; CI, confidence interval; ET, exchange transfusion; GA, gestational age; HDN, haemolytic disease of the newborn; ICTMG, International Collaboration for Transfusion Medicine Guidelines; IVIG, immunoglobulin; MD, mean difference; PT, phototherapy; RBC, red blood cell; RCT, randomized controlled trial; RR, relative risk; SR, systematic review.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDests License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
INTRODUCTION

Despite preventative strategies, haemolytic disease of newborn (HDN) continues to occur in 3–80/10,000 neonates/year.1,2 HDN occurs when maternal IgG antibodies reactive to paternal blood group antigens traverse the placenta and cause immune-mediated haemolysis of fetal red blood cells (RBCs). Alloimmunization can be triggered by more than 50 blood group antigens; the most severe disease involves RhD, Rhc and K antigens. When severe, HDN can be associated with significant morbidity, particularly neurocognitive deficits and mortality.3

First-line treatment for neonates with severe jaundice includes intensive phototherapy (PT). Intensive PT is defined by the American Academy of Paediatrics (AAP) as a spectral irradiance of at least 30 mW/cm²/nm delivered to as much of the infant’s surface area as possible.4 For intensive PT, the intensity of each PT light should be >30 mW/cm²/nm. For severe, non-responsive hyperbilirubinaemia, exchange transfusion (ET) is recommended to remove bilirubin, the implicated maternal alloantibodies and antibody-coated RBCs.4,5 Despite its therapeutic benefits, ETs can be associated with catheter-related infections, hypocalcaemia, thrombosis, haemorrhage, cardio-respiratory instability and necrotizing enterocolitis; ETs have a mortality rate up to 5%.7–10

Intravenous immunoglobulin (IVIG) is used to delay or avoid ET.4,5,11 IVIG blocks Fc receptors on macrophages which reduces destruction of antibody-coated RBCs, enhancing the clearance of maternal antibodies and lowering the circulating unconjugated bilirubin levels.12 Although a number of randomized, controlled trials (RCTs) have shown that IVIG is effective in decreasing the need for ETs, improve neurocognitive outcomes, reduce bilirubin level, reduce the frequency of red blood cell (RBC) transfusions and severity of anaemia, and/or reduce duration of hospitalization for neonates with Rh or ABO-mediated HDN. We used a systematic approach to search and review the literature and then develop recommendations from published data. These recommendations conclude that IVIG should not be routinely used to treat Rh or ABO antibody-mediated HDN. In situations where hyperbilirubinaemia is severe (and ET is imminent), or when ET is not readily available, the role of IVIG is unclear. High-quality studies are urgently needed to assess the optimal use of IVIG in patients with HDN.

KEYWORDS
alloimmunization, evidence-based guidelines, haemolytic disease of the newborn, intravenous immunoglobulin, pregnancy

Abstract

Haemolytic disease of the newborn (HDN) can be associated with significant morbidity. Prompt treatment with intensive phototherapy (PT) and exchange transfusions (ETs) can dramatically improve outcomes. ET is invasive and associated with risks. Intravenous immunoglobulin (IVIG) may be an alternative therapy to prevent use of ET. An international panel of experts was convened to develop evidence-based recommendations regarding the effectiveness and safety of IVIG to reduce the need for ETs, improve neurocognitive outcomes, reduce bilirubin level, reduce the frequency of red blood cell (RBC) transfusions and severity of anaemia, and/or reduce duration of hospitalization for neonates with Rh or ABO-mediated HDN. We used a systematic approach to search and review the literature and then develop recommendations from published data. These recommendations conclude that IVIG should not be routinely used to treat Rh or ABO antibody-mediated HDN. In situations where hyperbilirubinaemia is severe (and ET is imminent), or when ET is not readily available, the role of IVIG is unclear. High-quality studies are urgently needed to assess the optimal use of IVIG in patients with HDN.
(number or volume), severity of anaemia or duration of hospitalization.\textsuperscript{16,17}

\section*{Methods}

An international panel of haematologists, neonatologists and transfusion specialists was convened. A systematic search for articles published (1946–2021) in MEDLINE, EMBASE, NHS Economic Evaluation Database, HTA and Cochrane Central Register of Controlled Trials and SR was completed (Appendix S1) and the systematic review was registered in Prospero (CRD42019142072). Study inclusion criteria were: (1) original peer-reviewed; (2) at least five neonates with diagnosis or at risk of HDN; (3) comparing either of the following interventions: PT or ET, with IVIG; (4) reporting one of the following outcomes: bilirubin level, anaemia, frequency of RBC transfusions, neurocognitive outcome or mortality; (5) RCT or comparative trial; (6) English. A secondary search with a focus on ABO-mediated HDN was performed. Two reviewers (LL, NS) screened publications for eligibility, independently extracted data and assessed risk of bias using criteria established for the reporting of randomized and non-randomized studies.\textsuperscript{18–20} Meta-analyses were conducted if not available from previously published systematic reviews.

Recommendations were formulated on the basis of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) and the level of evidence was graded as high, moderate, low or very low.\textsuperscript{21,22} Recommendation strength was evaluated as strong or conditional. The panel ranked clinical outcomes relevant for the development of recommendations according to GRADE (Appendix S2) Web conferences and electronic correspondence were used to discuss the clinical questions and formulate recommendations. Electronic surveys were sent to members to assess agreement with recommendations. Disagreements were resolved by group discussions. If disagreements could not be resolved, a recommendation was accepted if the majority (≥50\%) agreed. Members recorded their disclosures but none were excluded from voting. The final guidance document was sent to numerous societies for feedback (Appendix S3).

The recommendations will be reviewed every two years from publication. If a study is published that may impact patients prior to that time, a comment will be added on the International Collaboration for Transfusion Medicine Guidelines (ICTMG) website (ictmg.org) along with the guideline and additional resources for physicians and patients.

\section*{Results}

\subsection*{Study Inclusion}

In all, 1242 abstracts were reviewed and 25 full-text articles were retrieved. Two systematic reviews (SRs),\textsuperscript{23,24} and two non-randomized studies\textsuperscript{25,26} met inclusion criteria (Figure 1). One Cochrane systematic review (SR)\textsuperscript{24} included nine RCTs (\(n = 658\)); Rh-mediated HDN (\(N = 5\)), ABO-mediated HDN (\(N = 1\)) and three studies included neonates with both ABO- and Rh-mediated HDN. The second SR included 12 RCTs (\(n = 426\)); Rh incompatibility alone in seven studies, ABO incompatibility in two studies, while three enrolled neonates with both Rh and ABO incompatibility.\textsuperscript{23}

The second SR\textsuperscript{23} included four studies not included in the Cochrane SR.\textsuperscript{24} The Cochrane SR included one study not included in the SR conducted by Lois and colleagues. The two retrospective studies focused on ABO incompatibility.\textsuperscript{25,26} For Rh-mediated HDN, data and analysis from both SRs were utilized to make recommendations regarding the benefit of IVIG for Rh-mediated HDN. For ABO-mediated HDN, data and analysis from one of the SRs\textsuperscript{23} were used to make recommendations for use of IVIG for ABO-mediated HDN as separate data were available for ABO incompatibility. The studies were conducted in diverse countries including Turkey, Egypt, Saudi Arabia, Iran, Germany, Brazil and the Netherlands.

Mortality, kernicterus, acute neurological impairment, chronic neurologic impairment and need for ET were ranked by the panel as critical for decision making, and the need for RBC transfusion, bilirubin level, anaemia and length of hospital stay were ranked as important (Appendix S2). Most of the included studies did not report on critical clinical outcomes; only two studies reported on one-\textsuperscript{27} and two-year\textsuperscript{28} outcomes.

\subsection*{Study Characteristics}

Details regarding study characteristics and risk of bias are summarized (Table 1, Appendices S4–S7). A number of the studies issued IVIG early or close to the time of delivery, before neonates developed significant hyperbilirubinaemia\textsuperscript{27–31} with the goal to prevent the need for ET. The majority of studies enrolled term neonates of 37 weeks gestational age (GA) or greater,\textsuperscript{29,32–37} two included neonates of all GAs,\textsuperscript{27,28} one enrolled only preterm neonates,\textsuperscript{38} and two studies did not describe details of GA.\textsuperscript{30,39}

\subsection*{Summary of Results}

The Cochrane SR\textsuperscript{24} combined the outcomes for neonates with Rh-mediated HDN and ABO-mediated HDN who received PT alone to those who received PT and IVIG. The IVIG group had a reduced need for an ET [relative risk (RR) 0.35; 95\% confidence interval (CI) –0.25, 0.49], had a significantly lower maximum total serum bilirubin level [mean difference (MD) 25.4 mmol lower; 95\% CI –34 to –16.7] and a shorter duration of PT (MD 0.98 days less with IVIG, 95\% CI –1.31 to 0.66). Use of top-up RBC transfusion in the first week or after the first week was not significantly different between the two groups (first week: RR 1.05; 95\% CI –0.65 to 1.69; following first week: RR 1.16; 95\% CI –0.97 to 1.38).
Shorter duration of hospitalization was reported for the IVIG group (MD −1.34 days, 95% CI −1.6 to −1.09). Mortality, keri- nicterus as well as acute and chronic neurologic impairment were not reported.

For neonates with Rh-mediated HDN, the Cochrane SR included seven studies with 371 neonates and compared PT alone and PT with IVIG. IVIG resulted in a reduction in use of ET (RR 0.38, 95% CI 0.25–0.58), similar need for RBC transfusions during the first week and thereafter (first week; RR 1.08, 95% CI 0.65–1.77; after first week: RR 1.09, 95% CI 0.92–1.28), lowered maximum bilirubin levels (MD −21.77 mmol/l; 95% CI −30.86 to −12.67) and shortened duration of PT (MD −1.23 days; 95% CI −1.43 to −1.02). Review of the quality of these studies confirmed a high risk of bias.

Louis’ analysis described significant reduction in the need for ET (RR 0.23, 95% CI 0.13–0.4), duration of PT (MD −1.1, 95% CI −1.7 to −0.6) and duration of hospitalization (MD −1.1, 95% CI −2.4 to −0.2) but studies had a high risk of bias (six studies, 236 neonates with Rh incompatibility). IVIG did not affect the peak serum bilirubin level (MD −24.9; 95% CI −68.4 to 18.6) or the need for top-up transfusions (RR 1.2; 95% CI 0.4–3.9). Studies with low risk of bias (three studies,
190 Rh-incompatible neonates) revealed no difference in the need for ET (RR 0.82, 95% CI 0.53–1.26) or any secondary outcomes.23

For neonates with ABO-mediated HDN, data from five RCTs (N = 350) were included.23 IVIG reduced the number of ETs (RR 0.31; 95% CI 0.18–0.55), peak serum bilirubin levels (MD −60.6; 95% CI −83.2 to −37.9), duration of PT (MD −0.7; 95% CI −1.1 to −0.4) and duration of hospitalization (MD −1.2; 95% CI −1.8 to −0.5), but it did not reduce the need for top-up transfusion (RR = 1.7; 95% CI 0.6–5.3). These studies displayed a high risk of bias, with significant heterogeneity and small sample sizes. The two retrospective studies did not find a difference in bilirubin, haemoglobin or duration of PT.25,26

Subgroup analysis was performed by Louis to compare outcomes between Rh-incompatible neonates who received IVIG prophylaxis (six studies, n = 300). Studies with a high risk of bias (three studies, 110 neonates) described a reduction in ET with IVIG (RR 0.21; 95% CI 0.1–0.45), whereas studies with low risk of bias did not (three studies, 190 neonates, RR 0.82; 95% CI 0.53–1.26).23

Rationale for recommendation regarding use of IVIG for Rh-mediated HDN

The majority of the studies included were considered to have a high risk of bias due to heterogeneity and small sample sizes. When the moderate quality randomized, placebo-controlled blinded trials with low risk of bias were analysed separately,27,28 IVIG did not decrease the need for ET (0.98, 95% CI 0.48–1.98), the need for a RBC transfusion within the first week of life (RR 1.18; 95% CI 0.7–2) or following the first week (RR 1.01; 95% CI 0.8–1.27) and did not decrease the mean serum bilirubin level (MD 0.93 mol/l; 95% CI 23.94–25.79). These two studies included 172 neonates (either >32 weeks GA27 or 35 weeks GA28) with RhD- and Rhc-mediated HDN, who received IVIG within the first 4–6 h of life. Eighty-seven patients received IVIG and 85 received a placebo. The GRADE certainty of evidence was considered moderate (Tables 2 and 3). The results of these higher-quality trials were utilized to make recommendations regarding prophylactic use of IVIG for Rh-mediated HDN.

Overall indications for PT and criteria for ET were not detailed. Intensity of PT treatments has advanced over the past decade,41 and neonates in the more recent high-quality studies may have received more intensive treatments than neonates treated in the earlier studies. Only three of the included studies,27,28,32 provided intensive PT as per AAP guidelines.4 One study used three overhead lights from a single angle,36 and a second study did not use a PT blanket.35 The rest of the studies did not describe the intensity of the PT in detail. Allocation concealment was generally not used (Table 4).

Additionally, definitions of anaemia and pre-transfusion haemoglobin thresholds were not provided32,36 or differed among studies, which may have led to different transfusion decisions and outcomes. Finally, only two studies used predefined criteria for hospital discharge. Due to the variability between studies in the definitions used for the outcome measures, the results of the two studies with moderate certainty of evidence of effects, and the potential risks of IVIG, routine prophylactic use of IVIG for Rh HDN was not recommended.

All of the studies included in this analysis reported that there were no definitive short-term adverse reactions specifically related to IVIG. Two of the nine studies did report adverse events, but it was unclear if these were secondary to IVIG or ET. The first study reported that 10 neonates who received ET were treated for sepsis.35 The second study described an infant who received IVIG and developed sepsis and brain abscess secondary to Bacillus cereus a few days after ET; IVIG and cultures of blood products used for ET were sterile. It was hypothesized that the sepsis may have been related to the umbilical catheterization and ET.28

Recommendation for management of Rh-mediated HDN

In neonates with Rh-mediated HDN, routine IVIG is not recommended to reduce the need for ET (low certainty of evidence of effects, conditional recommendation).

Studies that focus on HDN secondary to other non-ABO antibodies (e.g. Rhc, K, Jk<sup>+</sup>) have not been performed, but the same recommendations would apply.

Rationale for recommendation for IVIG for ABO-mediated HDN

ABO incompatibility between mother and fetus occurs in approximately 20% of all pregnancies; HDN only occurs in 1% of these pregnancies.42 ABO-mediated HDN occurs almost exclusively in group O mothers with non-O neonates and unlike Rh-mediated HDN, can occur during the first pregnancy. Compared to Rh-mediated incompatibilities, ABO-mediated incompatibility is associated with a lower risk of significant hyperbilirubinaemia and readmission for jaundice. Most neonates are asymptomatic or experience mild jaundice and neonatal anaemia is rare.43–45 At times, non-immune causes of jaundice including physiologic jaundice, poor feeding/dehydration and decreased milk production may exacerbate the hyperbilirubinaemia. ETs are infrequently performed, but may be needed due to delayed access to PT (e.g. remote areas) or lack of a universal bilirubin screening strategy.

ABO incompatibility is associated with less severe HDN as A and B antibodies are expressed on fetal tissues lowering the titre of maternal anti-A or anti-B in the fetal circulation, leaving less to bind to fetal RBCs. Secondly, soluble A and B substances in fetal/neonatal plasma can bind maternal anti-A or anti-B, leaving less antibody available to bind to fetal/neonatal RBCs. In addition, allo-antibodies reacting with A and B antigens have a weaker affinity than those binding with
| Author, year | Criteria for study inclusion | Dose of IVIG | Prophylactic IVIG** Y/N | Details about use of IUT recorded Y/N |
|---|---|---|---|---|
| Alpay, 1999<sup>37</sup> | (1) ABO/Rh incompatibility (2) Positive DAT (3) Hyperbilirubinaemia (>204 mmol/l) (4) Elevated reticulocyte count (≥10%) | 1 g/kg | N | NR |
| Beken, 2014<sup>25</sup> | (1) ABO incompatibility (2) Positive DAT | 1 g/kg | NR | NR |
| Dagoglu, 1995<sup>29</sup> | (1) Rh incompatibility (2) Positive DAT | 500 mg/kg | Y | NR |
| Demirel, 2011<sup>26</sup> | (1) ABO incompatibility and (2) Positive DAT (3) Reticulocytosis | 1 g/kg or 2 g/kg | N | NR |
| Elalfy, 2011<sup>12</sup> | (1) Rh incompatibility (2) Positive DAT (3) Elevated indirect hyperbilirubinaemia requiring PT in the first 12 h of life and/or rising by 0.5 mg/dl/h (4) Term newborn >38 wks GA (5) High reticulocyte count | 500 mg/kg and 1 g/kg | N | Y |
| Garcia, 2004<sup>38d</sup> | (1) Rh incompatibility | 0.75 g/kg daily × 3 days | Y<sup>e</sup> | Y |
| Huang, 2006<sup>44d</sup> | (1) ABO incompatibility (2) Positive DAT (3) Term (4) Titre >1:128 | 1 g/kg | N | NA |
| Miqdad, 2004<sup>35</sup> | (1) ABO incompatibility (2) DAT positive (3) Hyperbilirubinaemia Bilirubin >8.5 mmol/l/h or if bilirubin >170 mmol/l/h, 204 mmol/h or 238 mmol/h at <12, <18 or <24h, respectively IVIG if bilirubin rising by >8.5 mmol/l/h | 500 mg/kg | N | NR |
| Nasser, 2006<sup>33</sup> | (1) ABO/Rh incompatibility (2) Positive DAT (3) Hyperbilirubinaemia (>0.5 mg/dl/h) (4) Bilirubin levels below ET criterion on admission (5) GA >37 weeks | 500 mg/kg every 12 hs, total 3 doses | N | Within 2–4 h of admission Median 18–22 h |
| Pishva N, 2000<sup>40</sup> | (1) Rh/ABO incompatibility (2) Positive DAT (3) History Rh-positive sibling | 400–600 mg/kg | Y<sup>e</sup> | Y |
| Rubo, 1992<sup>30</sup> | (1) Rh incompatibility (2) Positive DAT Excluded (1) Unconjugated bilirubin >4 mg/dl | 500 mg/kg | Y<sup>e</sup> | |
| Santos, 2013<sup>27</sup> | (1) Rh incompatibility (2) Positive DAT (3) Elevated bilirubin >4 mg/dl (4) >32 weeks GA | 500 mg/kg | Y | NR |
| Smits-Wintjens, 2011<sup>24</sup> | (1) Rh(D) or Rh(c) incompatibility (2) Positive DAT with eluate (3) Maternal antibody-dependent cell cytotoxicity test >50% predicting severe haemolysis (4) Antibody titre >1:64 (5) GA >35 weeks | 750 g/kg | Y | Y |
| Author, year | Criteria for study inclusion | Dose of IVIG | Details about use of IUT recorded | Details regarding phototherapy provided | Indication for ET | Haemoglobin threshold/trigger for transfusion (g/l) | Definition of anaemia |
|--------------|-----------------------------|-------------|----------------------------------|----------------------------------------|------------------|-----------------------------------------------|----------------------|
| Alpay, 1999  | (1) ABO/Rh incompatibility  | 1 g/kg      | N | NR | Y | Serum bilirubin >290 mmol and increased >17 mmol/h despite treatment | NRb | NR |
| Beken, 2014  | (1) ABO incompatibility     | 1 g/kg      | N | NR | Y | Conventional PT | Bilirubin increased by 1 mg/dl/h as per AAP guidelines | NR |
| Demirel, 2011| (1) ABO incompatibility     | 1 or 2 g/kg | N | NR | Yes | LED PT | Bilirubin level exceeded the limits defined by AAP | NR |
| Elalfy, 2011 | (1) Rh incompatibility      | 500 mg/kg   | Y | NR | Y | Fibre-optic blanket | Bilirubin increased by 1 mg/dl/h as per AAP guidelines | NR |
| Huang, 2006  | (1) ABO incompatibility     | 1 g/kg      | N | NA | NA | NA | NA | NA |
| Miqdad, 2004 | (1) ABO incompatibility     | 500 mg/kg   | Y | NR | NR | Y | Bilirubin ≥340 mmol/l (20 mg/dl) or if rising by 8.5 mmol/l/h (0.5 mg/dl/h) in neonates not receiving IVIG | <70 g/l | Hgb < 120 g/l anaemia at postnatal 6–12 weeks |
| Nasseri, 2006 | (1) ABO/Rh incompatibility | 500 mg/kg   | N | NR | Y | Double surface blue light PT | Bilirubin ≥20 mg/dl or rise by 1 mg/dl/h | <70 g/l | Hgb < 120 g/l at 2, 4, 6 weeks |
| Pishva N, 2000 | (1) Rh/ABO incompatibility | 400–600 mg/kg | Y | NR | NR | NR | NR | NR |
| Rubo, 1992   | (1) Rh incompatibility      | 500 mg/kg   | Yc | Y | Y | Quartz lamps or blue light | If unconjugated bilirubin exceeded modified curves by Site specific ET criteria by ≥34 mmol/l (2 mg/dl) | NR | NR |
| Santos, 2013 | (1) Rh incompatibility      | 500 mg/kg   | Y | NR | Y | Prophylactic high intensity PT | Total serum bilirubin level ≥340 mmol/l (20 mg/dl) or increased by 8.5 mmol/l/h (0.5 mg/dl/h) despite PT | NR | NR |
| Smits- Wintjens, 2011 | (1) Rh(D) or Rh(c) incompatibility | 750 mg/kg | Y | Y | Y | Intensive PT using white light with intensity of 12–20μW/cm²/nm | ET criteria as per AAP guidelines | <80 or <96 g/l with clinical symptoms of anaemia e.g. lethargy, feeding problems, need for O₂ or failure to thrive | NR |

NR: Not reported
protein antigens. Moreover, there are relatively few group A or B antigenic sites on neonatal RBC as AB antigens are not well developed in the fetus. Some suggest that neonates with severe jaundice and ABO incompatibility may not have been assessed for other non-immune haemolytic aetiologies (e.g. glucose 6-phosphate dehydrogenase deficiency). The recommendation to not provide IVIG routinely for HDN assumed to be secondary to ABO incompatibility between

**TABLE 1** (Continued)

| Author, year | Criteria for study inclusion | Dose of IVIG | Prophylactic IVIG? Y/N | Details about use of IUT recorded Y/N |
|--------------|-----------------------------|-------------|------------------------|--------------------------------------|
| Tanyer, 2001 | (1) ABO or Rh incompatibility, (2) Positive DAT (3) no risk factors (e.g. sepsis), (4) no prematurity (define?) (5) Bilirubin < ET level at birth | IVIG 500 mg/kg or 500 mg/kg daily for 3 days | Y | NR |
| Voto, 1995  | (1) Rh incompatibility (2) Positive DAT | 800 g/kg/d × 3 days | N | Y |

Abbreviations: AAP, American Academy of Paediatrics; DAT, direct antiglobulin test; ET, exchange transfusion; FTT, failure to thrive; GA, gestational age; Hgb, haemoglobin; h, hour; IVIG, intravenous immune globulin; IUT, intrauterine transfusion; LED, light-emitting diodes; N, No; NA, not available (full manuscript); NR, not recorded; PT, phototherapy; Y, yes.

*Prophylactic IVIG defined as preventative or routine IVIG administered shortly after birth prior to the development of significant jaundice.
Five patients transfused as haemoglobin dropped <87 g/L.
*Prophylactic IVIG ordered but did not provide exact time of administration.
Data obtained from Louis systematic review (article not available or published in Chinese).

**TABLE 2** Grading of Recommendations, Assessment, Development and Evaluation (GRADE) for Rh incompatibility (data from Zwiers et al.)

| Certainty assessment | No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations |
|----------------------|--------------|-------------|--------------|---------------|--------------|-------------|---------------------|
| Use of exchange transfusion (studies without a placebo control) | 5 | Randomized trials | Very serious* | Not serious | Seriousb | Not serious | None |
| Use of exchange transfusion (placebo-controlled trials) | 2 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None |
| Number of exchange transfusions per infant (studies without a placebo control) | 5 | Randomized trials | Very serious* | Not serious | Seriousb | Not serious | None |
| Number of exchange transfusions per infant (placebo-controlled trials) | 2 | Randomized trials | Not serious | Not serious | Seriousb | Not serious | None |
| Maximum total serum bilirubin level μmol/l (studies without a placebo control) | 4 | Randomized trials | Very serious* | Serious | Seriousc | Not serious | None |
| Maximum total serum bilirubin level μmol/l (placebo-controlled trials) | 2 | Randomized trials | Not serious | Not serious | Seriousc | Not serious | None |
| Duration of phototherapy (studies without a placebo control) | 3 | Randomized trials | Very serious* | Not serious | Not serious | Not serious | None |
| Duration of phototherapy (placebo-controlled trials) | 2 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None |
| Use of top up transfusion (studies without a placebo control) | 2 | Randomized trials | Very seriousc,d | Seriousd | Seriousc | Seriousc | None |
| Use of top up transfusion (placebo-controlled trials) | 1 | Randomized trials | Not serious | Not serious | Very seriousf | Serious | None |

*Studies were not blinded generally and a few were limited by lack of random sequence generation, selective reporting and incomplete reporting.
Indications for exchange were not consistent.
Serum bilirubin is dependent on other factors in addition to haemolysis such as postnatal age.
Haemoglobin concentrations for transfusion not reported.
Only one study had outcomes. The second had 0 events.
One study did not report haemoglobin concentrations for transfusion.
mother and neonate took into account not only the aspects above but also the lack of high-quality studies for ABO-mediated HDN, along with the low likelihood of significant jaundice and morbidity related to ABO-mediated HDN.

**Recommendation for management of ABO-mediated HDN**

In neonates at risk of ABO-mediated HDN, routine IVIG is not recommended to reduce the need for ET (very low certainty of evidence of effects, conditional recommendation).

The recommendations developed refer to routine use of IVIG for any neonates with Rh- or ABO-mediated HDN and hyperbilirubinaemia requiring PT, but not yet at the level requiring an ET. Routine use refers to prophylactic IVIG use to prevent progression to severe consequences of hyperbilirubinaemia. Recommendations could not be made for or against use of IVIG for neonates with rapidly rising bilirubin and emergent need for ET, as no studies have addressed this specific indication.

**Severe hyperbilirubinaemia unresponsive to phototherapy**

In neonates where hyperbilirubinaemia is severe (unresponsive to intensive PT) and requirement for ET is emergent, but not available on site within a timely manner, no evidence-based recommendations regarding the use of IVIG can be made. While awaiting transport to a facility where ET is available, first-line treatment is intensive PT.  Various non-evidence-based treatment suggestions have been described, but none can be endorsed at this time.

**DISCUSSION**

For jaundiced neonates with antibody-mediated HDN and severe hyperbilirubinaemia who do not respond to intensive PT, IVIG is sometimes administered with the goal of avoiding ET and decreasing neonatal morbidity. Studies with moderate certainty of evidence of effects suggest that early administration of IVIG (within a few hours of birth) as a preventative measure is not effective in reducing the need for ET, RBC transfusions or hyperbilirubinaemia in neonates with Rh isoimmunization. 27,28 In these studies, intensive PT may have treated the bilirubin rise early, and the use of IVIG may not have led to additional benefits. Currently, no studies with high certainty of evidence of effects have assessed the value of IVIG to avoid ET for ABO-mediated HDN; fortunately, ABO HDN rarely leads to severe HDN or the need for an ET, RBC transfusions or severe jaundice. Studies assessing treatment strategies for antibody-mediated HDN when hyperbilirubinaemia is severe and ET requirement is emergent were not available for recommendation development. If the diagnosis of severe jaundice is delayed or HDN occurs in remote hospitals or low-resource countries where intensive PT is not immediately available, IVIG may be considered, if ET is not readily available.

The benefit of using IVIG needs to balance risks. IVIG is a fractionated blood product manufactured from multiple donors. Previous literature has reported immediate (10%) and delayed (41%) adverse events following IVIG infusion in children, 47 including headaches, haemolysis 48 and aseptic meningitis. 49 For neonates, published reports of adverse events are limited and include apnoea, 50 haemolysis 51 and a higher incidence of necrotizing enterocolitis. 15 In addition, although fractionation leads to a virally inactivated product, the risk of viral transmission is not completely negligible.

**CONCLUSION**

The intent of this guidance document was to develop recommendations regarding the use of IVIG for Rh- and ABO-mediated HDN. We were unable to find studies that support the routine use of IVIG. Reducing the morbidity
and mortality of HDN and its treatments remains a priority and there continues to be a pressing need for additional collaborative research. Future, prospective multicentre studies with clearly defined inclusion criteria, detailed algorithms regarding use of PT and need for ETs, as well as standardized follow-up frequency and transfusion threshold guidelines would enable the question to be addressed properly. Due to the relative rarity of HDN, well-powered trials will be a challenge to execute. If small studies remain the most pragmatic approach, the only strategy for meaningful conclusions in future meta-analyses on HDN management is standardization of criteria for commencement and termination of intensive PT as well as criteria for ET and top-up RBC transfusions.

ACKNOWLEDGEMENTS

International Collaboration for Transfusion Medicine Guidelines (ICTMG) members: Arwa Al Riyami MD, FRCPC, Sultan Qaboos University Hospital, Oman; Shubha Allard, MD, FRCP, FRCPath, National Health Service Blood & Transplant, United Kingdom; Melissa Brouwers, PhD, University of Ottawa, Canada; Jeannie Callum, MD, FRCPC, Sunnybrooke Health Sciences Centre and University of Toronto, Canada; James Daly, MBBS, FRACP, FRCPA, Australian Red Cross Lifeblood, Australia; Gregory A. Denomme, PhD, FCSMLS(D), Versiti Blood Center of Wisconsin, United States; Lise Estcourt, MB BChir, MA(Cantab), MA(MEL), MSc, DLSHTM, DPhil, MRCP, FRCPA, National Health Services Blood & Transplant, United Kingdom; Dean Fergusson, PhD, MHA, Ottawa Hospital Research Institute, Canada; Mark Fung, MD, PhD, University of Vermont Medical Center, United States; Laura Green, MBBS, MD (Res), FRCP, FRCPA, National Health Service Blood & Transplant, United Kingdom; Andreas

TABLE 3 Grading of Recommendations, Assessment, Development and Evaluation (GRADE) for ABO incompatibility (data from Louis et al.)

| Certainty assessment | No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations |
|----------------------|----------------|--------------|--------------|---------------|--------------|-------------|---------------------|
| Need for exchange transfusion | 5 | Randomized trials | Very serious<sup>a,b</sup> | Not serious | Serious | Serious<sup>a</sup> | None |
| Number of exchange transfusions per infant | 3 | Randomized trials | Very serious<sup>b</sup> | Not serious | Serious<sup>a</sup> | Serious | None |
| Peak serum bilirubin (µmol/l) | 1 | Randomized trials | Very serious<sup>b,c,d</sup> | Very serious<sup>c</sup> | Very serious<sup>c</sup> | Serious | None |
| Duration of phototherapy | 3 | Randomized trials | Very serious<sup>b</sup> | Not serious | Serious | Not serious | None |
| Duration of hospitalization | 2 | Randomized trials | Very serious<sup>b</sup> | Not serious | Serious | Serious | None |
| Need for top up transfusion | 3 | Randomized trials | Very serious<sup>e</sup> | Not serious | Serious | Serious | None |

Abbreviations: CI, confidence interval; IVIG, intravenous immune globulin; MD, mean difference; RR, risk ratio.
<sup>a</sup>Definitions for need were not consistent.
<sup>b</sup>None of the trials used allocation concealment, had blinded participants, or used blinded outcome assessment. Selective reporting could not be determined.
<sup>c</sup>Only one study.
<sup>d</sup>Only one study.
<sup>e</sup>Variable reporting for haemoglobin concentrations for transfusion.

TABLE 4 International recommendations for use of intravenous immunoglobulin to manage haemolytic disease of the newborn

| Recommendations | In neonates with Rh-mediated HDN, routine<sup>a</sup> IVIG is not recommended to reduce the need for exchange transfusion (low certainty of evidence of effects, conditional recommendation) |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1              | In neonates with Rh-mediated HDN, routine<sup>a</sup> IVIG is not recommended to reduce the need for exchange transfusion (low certainty of evidence of effects, conditional recommendation) |
| 2              | In neonates at risk of ABO-mediated HDN, routine<sup>a</sup> IVIG is not recommended to reduce the need of exchange transfusion (very low certainty of evidence of effects, conditional recommendation) |

Abbreviations: HDN, haemolytic disease of the newborn; IVIG, intravenous immune globulin.
<sup>a</sup>Routine use refers to prophylactic IVIG use to prevent progression to severe consequences of hyperbilirubinaemia.
Table 3: Grading of Recommendations, Assessment, Development and Evaluation (GRADE) for ABO incompatibility (data from Louis et al.) 23

| Effect                                  | Relative (95% CI) | Absolute (95% CI) | Certaintyabcd | Importance |
|-----------------------------------------|-------------------|-------------------|---------------|------------|
| No. of patients                         | IVIG              | Control           |               |            |
| 13/174 (7.5%)                           | 46/176 (26.1%)    | RR 0.31 (0.18 to 0.55) | 180 fewer per 1000 (from 214 fewer to 118 fewer) | ⨁◯◯◯ | Very low | Critical |
| 112                                     | 114               | MD 0–0.2 (0.3 lower to 0.09 lower) |               |            |
| 45                                      | 48                | MD 60.6 μmol/l lower (83.2 lower to 38 lower) |               |            |
| 112                                     | 114               | MD 0.74 days lower (1.1 lower to 0.4 lower) |               |            |
| 56                                      | 58                | MD 1.2 days lower (1.8 lower to 0.51 lower) |               |            |
| 7/112 (6.3%)                            | 4/114 (3.5%)      | RR 1.7 (0.6 to 5.0) |               |            |

Abbreviations: CI, confidence interval; IVIG, intravenous immune globulin; MD, mean difference; RR, risk ratio.

aDefinitions for need were not consistent.
bNone of the trials used allocation concealment, had blinded participants, or used blinded outcome assessment. Selective reporting could not be determined.
cOnly one study.
dOnly one study.
eVariable reporting for haemoglobin concentrations for transfusion.

CONFLICT OF INTEREST
The authors have no financial or intellectual conflicts of interest to declare.

AUTHOR CONTRIBUTIONS
Dr Lieberman designed the study, identified and selected studies, extracted data, assessed methodologic quality and bias, and drafted the guideline manuscript; Dr Lopriore designed the study, and edited and approved the final manuscript; Dr Shehata identified and selected studies, extracted data, assessed methodologic quality and bias, and edited the guideline manuscript; Dr Landry identified and selected studies. All authors contributed to the development of recommendations, revision of recommendations, response to external reviewers, critically reviewing the manuscript, approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

DISCLAIMER
The purpose of this document is to provide guidance on the use of IVIG in the management of HDN based on published evidence. The recommendations are not intended to replace either the physicians’ clinical judgement of the specific case or the physicians’ personal experience. The final decision should be made by the treating physician in light of the current clinical details.
REFERENCES

1. Webb J, Delaney M. Red blood cell alloimmunization in the pregnant patient. Transfus Med Rev. 2018;32(4):213–9.

2. Lieberman LC, Callum J, Cohen R, Cseri-Gazdewich C, Ladhani N, Pendergrast J & Buckstein J Impact of red blood cell alloimmunization on fetal and neonatal outcomes: a single center cohort study. Transfusion. 2020;60(11):2537–46.

3. Rath MEA, Smits-Wintjens VEHJ, Lindenburg ITM, Folman CC, Brand A, van Kamp IL, et al. Postnatal outcome in neonates with severe rhesus c compared to rhesus D hemolytic disease. Transfusion. 2013;53(7):1580–5.

4. American Academy of Pediatrics Subcommittee on HI. Prevention of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.

5. Barrington KJSKCPS. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants. Paediatr Child Health. 2007;12Suppl B:18–128.

6. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks’ gestation: an update with clarifications. Pediatrics. 2009;124(4):1193–8.

7. Smits-Wintjens VE, Walther FJ, Lopriore E. Rhesus haemolytic disease of the newborn: postnatal management, associated morbidity and long-term outcome. Semin Fetal Neonatal Med. 2008;13(4):265–71.

8. Murki S, Kumar P. Blood exchange transfusion for infants with severe neonatal hyperbilirubinemia. Semin Perinatol. 2011;35(3):175–84.

9. Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics. 1997;99(5):E7.

10. Diamond LK, Allen FH Jr, Thomas WO Jr. Erythroblastosis fetalis. VII. Treatment with exchange transfusion. N Engl J Med. 1951;244(2):39–49.

11. Kubo S, Ariga T, Tsuneta H, Ishii T. Can high-dose intravenous immunoglobulin therapy be indicated in neonatal rhesus haemolysis? A successful case of haemolytic disease due to rhesus (c + E) incompatibility. Eur J Pediatr. 1991;150(7):507–8.

12. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127(2):315–23; quiz 24–5.

13. Amos RC, Jacob H, Leith W. Jaundice in newborn babies under 28 days: NICE guideline 2016 (CG98). Arch Dis Child Educ Pract. 2017;10(2):207–9.

14. Christensen RD, Ilstrup DJ, Baer VL, Lambert DK. Increased hemolysis after administering intravenous immunoglobulin to a neonate with erythroblastosis fetalis due to Rh hemolytic disease. Transfusion. 2015;55(6):1365–6.

15. Figuera-Aloy J, Rodriguez-Miguélez JM, Iriondo-Sanz M, Salvador- Roiges M-D, Botet-Mussons F, Carbonell-Estrany X. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics. 2010;125(1):139–44.

16. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88(1):F6–10.

17. Keir AK, Dunn M, Callum J. Should intravenous immunoglobulin be used in infants with isoaemimic haemolytic disease due to ABO incompatibility? J Paediatr Child Health. 2013;49(12):1072–8.

18. Shea BJ, Reeves BC, Wells G, Thuku M, Hamei C, Moram J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. bmj. 2017;358.

19. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;366:i4898.

20. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:i4898.

21. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.

22. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.

23. Louis D, More K, Oberoi S, Shah PS. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014;99(4):F325–31.

24. Zwiers C, Scheffer-Rath EAM, Lopriore E, de Haas M, Liley HG. Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev. 2018;3:1–64.

25. Beken S, Hirfanoglu I, Turkyilmaz C, Altuntas N, Unal S, Turan O, et al. Intravenous immunoglobulin G treatment in ABO hemolytic disease of the newborn, is it myth or real? Indian Journal of Hematology and Blood Transfusion. 2014;30(1):12–5.

26. Demirel G, Akar M, Celik IH, Erdove O, Uras N, Oguz SS, et al. Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates. Int J Hematol. 2011;93(6):700–3.

27. Santos MC, Sa C, Gomes SC Jr, Camacho LA, Moreira ME. The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial. Transfusion. 2013;53(4):777–82.

28. Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics. 2011;127(4):680–6.

29. Doguoglu T, Ovalli F, Samanci N, Bengisu E. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res. 1995;23(4):264–71.

30. Rubio J, Albrecht K, Lasch P, Laukotter E, Leititis J, Marsan D, et al. High-dose intravenous globulin globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr. 1992;121(1):93–7.

31. Mishra S, Cheema A, Agarwal R, Deorari A, Paul V. Oral zinc for the prevention of hyperbilirubinemia in neonates. Cochrane Database Syst Rev. 2015;7:1–12.

32. Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous immunoglobulin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn – a prospective randomized controlled trial. Eur J Pediatr. 2011;170(4):461–7.

33. Nasser F, Mamouri GA, Babaei H. Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Med J. 2006;27(12):1827–30.

34. Huang W-m, Chen H-w, Li N, Yang M, Jiao P-y. Clinical study of early interventions for ABO hemolytic disease of the newborn. Nan fang yi ke da xue xue bao = J South Med Univ. 2006;26(9):1350–5.

35. Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Almaz R (Eds). Intravenous Immunoglobulin (IVIG) Administration as a Treatment for Rh Hemolytic Jaundice in Mexico City. Pediatric Research. 2004: INT Pediatric Research Foundation, Inc.

36. Voto LS, Sexer H, Ferreiro G, Tavosnanska J, Orti J, Mathet ER, et al. Neonatal administration of high-dose intravenous immunoglobulin in rhesus hemolytic disease. J Perinat Med. 1995;23(6):443–51.
40. Pishva N, Madani A, Homayoon K. Prophylactic intravenous immunoglobulin in neonatal immune hemolytic jaundice. Irn J Med Sci. 2000;25:129–33.
41. Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F83–8.
42. Desjardins L, Blachman M, Chintu C, Gent M, Zipursky A. The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr. 1979;95(3):447–9.
43. Christensen RD, Baer VL, MacQueen BC, O’Brien EA, Ilstrup SJ. ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program. J Perinatol. 2018;38(5):517–25.
44. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015;2015:146–51.
45. Geaghan SM. Diagnostic Laboratory Technologies for the Fetus and Neonate with isoimmunization. Semin Perinatol. 2011;35(3):148–54.
46. Christensen RD, Lambert DK, Henry E, Eggert LD, Yaish HM, Reading NS, et al. Unexplained extreme hyperbilirubinemia among neonates in a multihospital healthcare system. Blood Cells Mol Dis. 2013;50(2):105–9.
47. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child. 2006;91(8):651–4.
48. Akman AO, Kara FK, Koksal T, Cakir BC, Karagol C, Sayli T. Association of hemolysis with high dose intravenous immunoglobulin therapy in pediatric patients: an open-label prospective trial. Transfus Apher Sci. 2017;56(4):531–4.
49. Bharath V, Eckert K, Kang M, Chin-Yee IH, Hsia CC. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center. Transfusion. 2015;55(11):2597–605.
50. Kumar A, Kapoor R, Basu S. Apnea as a complication of intravenous immunoglobulin therapy in a neonate. Indian J Pediatr. 2014;81(12):1415.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, et al. International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn. Br J Haematol. 2022;198:183–195. [https://doi.org/10.1111/bjh.18170](https://doi.org/10.1111/bjh.18170)